Lifesci Capital Issues Optimistic Forecast for ELVN Earnings

Enliven Therapeutics, Inc. (NASDAQ:ELVN) – Equities researchers at Lifesci Capital raised their FY2025 earnings estimates for shares of Enliven Therapeutics in a research report issued to clients and investors on Monday, March 17th. Lifesci Capital analyst S. Slutsky now anticipates that the company will earn ($2.54) per share for the year, up from their previous forecast of ($2.57). The consensus estimate for Enliven Therapeutics’ current full-year earnings is ($1.95) per share.

Separately, BTIG Research began coverage on shares of Enliven Therapeutics in a research note on Friday, December 13th. They set a “buy” rating and a $42.00 price target on the stock. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $38.25.

Enliven Therapeutics Trading Down 3.6 %

Shares of NASDAQ:ELVN opened at $20.28 on Wednesday. The business’s 50 day moving average is $21.45 and its 200-day moving average is $23.80. The firm has a market capitalization of $990.86 million, a PE ratio of -10.67 and a beta of 1.04. Enliven Therapeutics has a 1-year low of $14.50 and a 1-year high of $30.03.

Enliven Therapeutics (NASDAQ:ELVN) last released its earnings results on Thursday, March 13th. The company reported ($0.46) earnings per share for the quarter, beating the consensus estimate of ($0.53) by $0.07. The company had revenue of $0.03 million during the quarter.

Institutional Trading of Enliven Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. California State Teachers Retirement System grew its holdings in Enliven Therapeutics by 10.2% during the 4th quarter. California State Teachers Retirement System now owns 20,914 shares of the company’s stock worth $471,000 after acquiring an additional 1,940 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Enliven Therapeutics by 67.1% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 43,714 shares of the company’s stock valued at $984,000 after purchasing an additional 17,546 shares during the last quarter. Stempoint Capital LP acquired a new stake in shares of Enliven Therapeutics in the fourth quarter valued at approximately $2,176,000. Polar Capital Holdings Plc lifted its holdings in Enliven Therapeutics by 267.6% during the 4th quarter. Polar Capital Holdings Plc now owns 2,389,668 shares of the company’s stock worth $53,768,000 after buying an additional 1,739,668 shares in the last quarter. Finally, ProShare Advisors LLC lifted its holdings in Enliven Therapeutics by 29.5% during the 4th quarter. ProShare Advisors LLC now owns 12,229 shares of the company’s stock worth $275,000 after buying an additional 2,788 shares in the last quarter. 95.08% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Enliven Therapeutics

In other news, CFO Benjamin Hohl sold 1,000 shares of the firm’s stock in a transaction that occurred on Friday, January 3rd. The shares were sold at an average price of $25.04, for a total transaction of $25,040.00. Following the completion of the sale, the chief financial officer now owns 13,000 shares of the company’s stock, valued at approximately $325,520. This trade represents a 7.14 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, COO Anish Patel sold 21,700 shares of the firm’s stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $24.18, for a total value of $524,706.00. The disclosure for this sale can be found here. Insiders have sold 47,784 shares of company stock worth $1,092,375 over the last three months. Company insiders own 29.20% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.